Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Sep 25, 2026
Clearpoint Neuro, Inc. (CLPT)
A forensic read on Clearpoint Neuro, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
F · Poor — capital at risk
Forensic grade
Grey Zone
Financial health
1.5
Distress distance
Watch
Earnings quality
5
Forensic signals
-11.7
P / E (ttm)
-91.1%
ROE
$457M
Market cap
0.00%
Dividend yield
17.8%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern, valuation). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Clearpoint Neuro, Inc. earns an F (Poor — capital at risk) forensic quality grade, and its balance-sheet distress test reads 1.5, placing it in the Grey zone. 5 forensic signals were flagged in its latest SEC filings, led by accruals ratio (% of noa).
What the filings flag
+142.0%
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets grew +142.0% relative to their own average in FY2025 — scaled by NOA itself, not by total assets, which is what the Forensic Screens card's own accrual row divides by. Accruals are building sharply — a large slice of profit sits in operating assets, not cash. An accrual is a claim that still has to be collected or written down, so the gap resolves in a later period whichever way it goes. The build is led by receivables up +39% against revenue +18% and inventory up +22% against +16% in cost of sales. A cash-flow measure on the same base disagrees: reported earnings ran behind operating cash by 9% of net operating assets, against an accruals ratio of 142.0%. The two are computed differently: the accruals ratio is the change in net operating assets over average net operating assets, while the cash-flow figure is net income less operating cash flow over that same average. Read them as two results, not one.
65d DSO
FY2024→FY2025
Receivables vs revenue.Days sales outstanding moved from 55 to 65 days FY2024→FY2025 (receivables +39% vs revenue +18%). Receivables are outrunning sales — a flag for aggressive revenue recognition or slipping collections. Across FY2023–FY2025 the day count ran 49 → 55 → 65 days — the latest step continues a climb that was already under way, which is the persistence that separates a collection problem from a busy quarter. Deferred revenue was roughly flat (-12%) over the same period, which doesn't corroborate a benign upfront-billing explanation for the receivables build. Measured against the same quarter twelve months earlier — like-for-like on the calendar, so an ordinary seasonal build cannot produce it — receivables took longer to collect in 3 consecutive quarters (Dec 2025 +2, Mar 2026 +26, Jun 2026 +28 days). In the latest of them the receivable balance grew +97% against sales +18%, so more of a quarter's billings were still outstanding at the period end than a year earlier — money the company has recognized and not yet been paid. Both figures are measured on period-end balances rather than the beginning-plus-ending average, because averaging needs the balance a year before every reading — FY2024's opening balance is on file, but across the 3 fiscal years read here (FY2023–FY2025) the average yields only 2 day counts (1 step), too few to tell a climb from one year's move.
Key fundamentals
Latest Revenue$37.0M
Revenue Growth YoY+17.8%
Revenue CAGR (2yr)+24.2%
Net Margin-69.1%
Free Cash Flow-$24.4M
Return on Equity-91.1%
Debt / Equity1.75x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Clearpoint Neuro, Inc.'s actual 10-K/10-Q/8-K filings?
Data from SEC EDGAR public filings · metrics as of Sep 25, 2026. Forensic signals flag probability, not certainty.
-46.5%
FY2025
Return on invested capital.Return on invested capital is -46.5% in the latest fiscal year, against -146.7% in FY2023, having run between -178.5% and -46.5% across FY2023–FY2025 with no direction held. After-tax operating profit was ($18M) in FY2023 and ($19M) in FY2025, with operating income at -93.7% of revenue in FY2023, -62.9% in FY2024 and -65.4% in FY2025. The capital base behind it grew +240% across FY2023–FY2025, from $12M to $41M, and the return did not fall doing it, so the dollars added over that window earned at least the -146.7% the older base was already earning.
+7.3%/yr
FY2023–FY2025
Share-count dilution.Diluted share count changed +15% over the last 2 years to FY2025 (+7.3%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~7.3% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~13%.
22% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 22% of revenue in FY2025 — about $0.29 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 7.3% a year, and the rate is falling. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.
Clearpoint Neuro, Inc. (CLPT) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy